MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer

Du,Binbin; Wang,Xiaoying; Wu,Dewang; Wang,Tao; Yang,Xiongfei; Wang,Jiankai; Shi,Xinlong; Chen,Lingjuan; Zhang,Weisheng

doi:10.3892/mmr.2018.9215

MicroRNA expression profiles identify biomarkers for predicting the response to chemoradiotherapy in rectal cancer

Authors:
- Binbin Du
- Xiaoying Wang
- Dewang Wu
- Tao Wang
- Xiongfei Yang
- Jiankai Wang
- Xinlong Shi
- Lingjuan Chen
- Weisheng Zhang
View Affiliations

Affiliations: Department of Anorectal Surgery, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China, Department of Radiotherapy, Gansu Provincial Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: June 25, 2018 https://doi.org/10.3892/mmr.2018.9215
Pages: 1909-1916
Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neoadjuvant chemoradiotherapy (nCRT) following surgery significantly improves the survival rate of patients with rectal cancer. However, nCRT is associated with significant adverse symptoms and high medical costs. Therefore, it is important to investigate potential biomarkers for the prediction of the response to nCRT in patients with rectal cancer. The present study identified candidate biomarkers for predicting a complete response (CR) to nCRT in patients with rectal cancer and investigated the associated mechanisms. Microarray data (accession no. GSE29298) was downloaded from the Gene Expression Omnibus database. Differentially expressed microRNAs (miRNAs/miR) were screened between the pathological CR (pCR) group and no pCR (incomplete response) group. miRNA target genes were predicted using the miRWalk 2.0 online tool and subjected to Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Furthermore, a miRNA co‑regulatory network was constructed and disease‑associated genes were predicted. The results demonstrated that a total of 36 upregulated and 5 downregulated miRNAs were identified between the two groups. Among these differentially expressed miRNAs, miR‑548c‑5p, miR‑548d‑5p and miR‑663a were significantly associated with a CR to nCRT. The co‑regulatory network and pathway analysis indicated that miR‑548c‑5p and miR‑548d‑5p may function together through stem cell pluripotency and ubiquitin‑mediated proteolysis signaling pathways. Furthermore, the prediction of disease‑associated genes demonstrated that miR‑548c‑5p/miR‑548d‑5p and miR‑663a may regulate genes associated with rectal cancer, including mutated in colorectal cancers (MCC) and adenomatous polyposis coli (APC), and colorectal neoplasms, including interleukin‑6 signal transducer (IL6ST), cell cycle checkpoint kinase 2 (CHEK2), marker of proliferation Ki‑67 (MKI67), cadherin 7 (CDH7), calreticulin (CALR) and transforming growth factor β1 (TGFB1). Therefore, miR‑548c‑5p, miR‑548d‑5p and miR‑663a are promising candidate biomarkers for predicting a CR to nCRT. miR‑548c‑5p/miR‑548d‑5p may be associated with a CR by regulating IL6ST, CHEK2, MKI67 and MCC. In addition, it may function through the pluripotency of stem cells and ubiquitin‑mediated proteolysis signaling pathways. miR‑663a may be associated with a CR to nCRT by targeting CDH7, CALR, APC and TGFβ1. Thus, the miRNA biomarkers investigated in the present study may represent novel therapeutic targets for the prediction and eventual improvement of the response to nCRT in patients with rectal cancer.

View Figures

View References

1	Zheng S and Cai S: Colorectal cancer epidemiology and prevention study in China. Chinese-German J Clinical Oncol. 2:72–75. 2003. View Article : Google Scholar
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
4	Dusek L, Muzik J, Kubasek M, Koptikova J, Zaloudik J and Vyzula R: Epidemiology of Malignant Tumours in the Czech Republic. http://www.svod.czSeptember 12–2013
5	Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al: Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 324:709–715. 1991. View Article : Google Scholar : PubMed/NCBI
6	Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, et al: Multidisciplinary rectal cancer management: 2nd european rectal cancer consensus conference (EURECA-CC2). Radiother Oncol. 92:148–163. 2009. View Article : Google Scholar : PubMed/NCBI
7	Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, et al: Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
8	Engels B, Gevaert T, Sermeus A and Ridder MD: Current status of intensified neo-adjuvant systemic therapy in locally advanced rectal cancer. Front Oncol. 2:472012. View Article : Google Scholar : PubMed/NCBI
9	Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al: Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar : PubMed/NCBI
10	Martin ST, Heneghan HM and Winter DC: Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 99:918–928. 2012. View Article : Google Scholar : PubMed/NCBI
11	Suárez J, Vera R, Balén E, Gómez M, Arias F, Lera JM, Herrera J and Zazpe C: Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer. Colorectal Dis. 10:563–568. 2008. View Article : Google Scholar : PubMed/NCBI
12	Azizian A, Gruber J, Ghadimi BM and Gaedcke J: MicroRNA in rectal cancer. World J Gastrointest Oncol. 8:416–426. 2016. View Article : Google Scholar : PubMed/NCBI
13	Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol. 7:1952012. View Article : Google Scholar : PubMed/NCBI
14	Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP and Odenthal M: Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol. 39:409–415. 2011.PubMed/NCBI
15	Kheirelseid EA, Miller N, Chang KH, Curran C, Hennessey E, Sheehan M, Newell J, Lemetre C, Balls G and Kerin MJ: miRNA expressions in rectal cancer as predictors of response to neoadjuvant chemoradiation therapy. Int J Colorectal Dis. 28:247–260. 2013. View Article : Google Scholar : PubMed/NCBI
16	Lopes-Ramos CM, Habr-Gama A, Bde Quevedo S, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA, Gama-Rodrigues J, Camargo AA, et al: Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics. 7:682014. View Article : Google Scholar : PubMed/NCBI
17	Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S and Pepe S: A Specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 83:1113–1119. 2012. View Article : Google Scholar : PubMed/NCBI
18	Smyth BGK: Limma: Linear models for microarray dataBioinformatics and Computational Biology Solutions Using R and Bioconductor. Springer; pp. 397–420. 2005, View Article : Google Scholar
19	Griffiths-Jones S: miRBase: The microRNA sequence database. Methods Mol Biol. 342:129–138. 2006.PubMed/NCBI
20	Griffiths-Jones S: miRBase: microRNA sequences and annotation. Curr Protoc Bioinformatics. 29:12.9.1–12.9.10. 2010.
21	Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI
22	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
23	Maqbool A, Lattke M, Wirth T and Baumann B: Sustained, neuron-specific IKK/NF-κB activation generates a selective neuroinflammatory response promoting local neurodegeneration with aging. Mol Neurodegener. 8:402013. View Article : Google Scholar : PubMed/NCBI
24	Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
25	Davis AP, Grondin CJ, Lennonhopkins K, Saraceni-Richards C, Sciaky D, King BL, Wiegers TC and Mattingly CJ: The Comparative Toxicogenomics Database's 10th year anniversary: Update 2015. Nucleic Acids Res. 43:(Database issue). D914–D920. 2015. View Article : Google Scholar : PubMed/NCBI
26	Semenza GL: HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 13:167–171. 2001. View Article : Google Scholar : PubMed/NCBI
27	Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, et al: Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 292:468–472. 2001. View Article : Google Scholar : PubMed/NCBI
28	Fang L, Zhang HB, Li H, Fu Y and Yang GS: miR-548c-5p inhibits proliferation and migration and promotes apoptosis in CD90(+) HepG2 cells. Radiol Oncol. 46:233–241. 2015.
29	Mandal P, Bhattacharjee B, Das Ghosh D, Mondal NR, Chowdhury Roy R, Roy S and Sengupta S: Differential expression of HPV16 L2 gene in cervical cancers harboring episomal HPV16 genomes: Influence of synonymous and non-coding region variations. PLoS One. 8:e656472013. View Article : Google Scholar : PubMed/NCBI
30	Knüpfer H and Preiss R: Serum interleukin-6 levels in colorectal cancer patients-a summary of published results. Int J Colorectal Dis. 25:135–140. 2010. View Article : Google Scholar : PubMed/NCBI
31	Waldner MJ, Foersch S and Neurath MF: Interleukin-6-A Key regulator of colorectal cancer development. Int J Biol Sci. 8:1248–1253. 2012. View Article : Google Scholar : PubMed/NCBI
32	Kilpivaara O, Laiho P, Aaltonen LA and Nevanlinna H: CHEK2 1100delC and colorectal cancer. J Med Genet. 40:e1102003. View Article : Google Scholar : PubMed/NCBI
33	Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, et al: The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype. Am J Hum Genet. 72:1308–1314. 2003. View Article : Google Scholar : PubMed/NCBI
34	Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA and Nevanlinna H: CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet. 43:e342006. View Article : Google Scholar : PubMed/NCBI
35	Hofstädter F, Knüchel R and Rüschoff J: Cell proliferation assessment in oncology. Virchows Arch. 427:323–341. 1995. View Article : Google Scholar : PubMed/NCBI
36	Dalerba P, Kalisky T, Sahoo D, Rajendran PS, Rothenberg ME, Leyrat AA, Sim S, Okamoto J, Johnston DM, Qian D, et al: Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol. 29:1120–1127. 2011. View Article : Google Scholar : PubMed/NCBI
37	Rau B, Sturm I, Lage H, Berger S, Schneider U, Hauptmann S, Wust P, Riess H, Schlag PM, Dörken B and Daniel PT: Dynamic Expression Profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Onco. 21:3391–3401. 2003. View Article : Google Scholar
38	Kim NK, Park JK, Lee KY, Yang WI, Yun SH, Sung J and Min JS: p53, BCL-2, and Ki-67 expression according to tumor response after concurrent chemoradiotherapy for advanced rectal cancer. Ann Surg Oncol. 8:418–424. 2001. View Article : Google Scholar : PubMed/NCBI
39	Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, et al: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science. 251:1366–1370. 1991. View Article : Google Scholar : PubMed/NCBI
40	Cawkwell L, Lewis FA and Quirke P: Frequency of allele loss of DCC, p53, RBI, WT1, NF1, NM23 and APC/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer. 70:813–818. 1994. View Article : Google Scholar : PubMed/NCBI
41	Kong D, Li Y, Wang Z and Sarkar FH: Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins? Cancers (Basel). 3:716–729. 2011. View Article : Google Scholar : PubMed/NCBI
42	Aberle H, Bauer A, Stappert J, Kispert A and Kemler R: beta-catenin is a target for the ubiquitin- proteasome pathway. EMBO J. 16:3797–3804. 1997. View Article : Google Scholar : PubMed/NCBI
43	Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B and Kinzler KW: Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1787–1790. 1997. View Article : Google Scholar : PubMed/NCBI
44	Zhu L, Chen H, Zhou D, Li D, Bai R, Zheng S and Ge W: MicroRNA-9 up-regulation is involved in colorectal cancer metastasis via promoting cell motility. Med Oncol. 29:1037–1043. 2012. View Article : Google Scholar : PubMed/NCBI
45	Schmalhofer O, Brabletz S and Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
46	Munemitsu S, Albert I, Souza B, Rubinfeld B and Polakis P: Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci USA. 92:3046–3050. 1995. View Article : Google Scholar : PubMed/NCBI
47	Gul IS, Hulpiau P, Saeys Y and Van RF: Evolution and diversity of cadherins and catenins. Exp Cell Res. 358:3–9. 2017. View Article : Google Scholar : PubMed/NCBI
48	Peng RQ, Chen YB, Ding Y, Zhang R, Zhang X, Yu XJ, Zhou ZW, Zeng YX and Zhang XS: Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol. 16:2428–2434. 2010. View Article : Google Scholar : PubMed/NCBI